Huang YLA, et al. - Given the high effectiveness of daily oral preexposure prophylaxis (PrEP) in preventing HIV infection if used adherently throughout periods of HIV risk, researchers here estimated PrEP persistence among cohorts of persons with commercial or Medicaid insurance. The IBM MarketScan Research Database provided data of 11,807 commercially insured and 647 Medicaid insured persons with PrEP prescriptions. The analysis revealed the persistence with PrEP for 12 months among more than half of the commercially insured persons who initiated PrEP, compared with a third of those with Medicaid. After adjusting for covariates, non-persistence was observed in correlation with the female gender (Hazard Ratio [HR] = 1.81) and younger age (18-24 years: HR = 2.38). Findings suggest determining the reasons for non-persistence to promote persistent PrEP use, and to develop interventions designed for the diverse needs of at-risk populations.